CA9 and neoplasm: As illustrated by cell viability data (Fig. 6, A and B), Sul-L1-RGD could significantly inhibit the survival of tumor cells under hypoxia conditions, and the inhibitory activity of Sul-L1-RGD was comparable to that of SLC-0111, a CAIX inhibitor in phase Ib/II clinical trials (Fig. 6, A and C).